Complete Filing Data
Maze Therapeutics, Inc. reported Stockholders Equity Including Portion Attributable To Noncontrolling Interest of $354.97 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Maze Therapeutics, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 |
|---|---|---|
| Net Income * | -$131.1M | $52.2M |
| Research And Development Expense | $108.4M | $83.5M |
| Operating Income Loss | -$142.9M | $57.6M |
| Operating Expenses | $142.9M | $109.9M |
| General And Administrative Expense | $34.5M | $26.4M |
| Net Income Loss Available To Common Stockholders Diluted | -$131.1M | $3.4M |
| Net Income Loss Available To Common Stockholders Basic | -$131.1M | $3.4M |
| Income Tax Expense Benefit | $0.00 | $1.2M |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$131.1M | $53.4M |
| Revenue From Contract With Customer Excluding Assessed Tax | $167.5M | |
| Comprehensive Income Net Of Tax | -$131.0M | $52.2M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Net Income * | -$30.1M | -$33.7M | -$32.8M | -$24.8M | $139.1M | -$32.5M |
| Research And Development Expense | $25.2M | $28.1M | $27.6M | $19.9M | $19.5M | $21.9M |
| Operating Income Loss | -$33.0M | -$36.5M | -$35.4M | -$24.2M | $139.6M | -$28.0M |
| Operating Expenses | $33.0M | $36.5M | $35.4M | $26.7M | $25.4M | $28.0M |
| General And Administrative Expense | $7.8M | $8.4M | $7.8M | $6.9M | $5.9M | $6.1M |
| Net Income Loss Available To Common Stockholders Diluted | -$30.1M | -$33.7M | -$24.8M | $13.9M | ||
| Net Income Loss Available To Common Stockholders Basic | -$30.1M | -$33.7M | -$24.8M | $14.1M | ||
| Income Tax Expense Benefit | $0.00 | $0.00 | -$279.0K | $1.7M | ||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$30.1M | -$33.7M | -$25.0M | $140.8M | ||
| Revenue From Contract With Customer Excluding Assessed Tax | $0.00 | $2.5M | $165.0M | |||
| Comprehensive Income Net Of Tax | -$30.0M | -$24.8M |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Stockholders Equity * | $355.0M | -$311.2M | -$373.8M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $190.3M | $197.9M | $30.2M |
| Cash And Cash Equivalents At Carrying Value | $189.2M | $196.8M | |
| Retained Earnings Accumulated Deficit | -$489.5M | -$358.4M | |
| Restricted Cash Noncurrent | $1.1M | $1.1M | |
| Restricted Cash | $1.1M | $1.1M | |
| Property Plant And Equipment Net | $5.0M | $6.7M | |
| Prepaid Expense And Other Assets Current | $7.8M | $4.9M | |
| Other Operating Activities Cash Flow Statement | $21.0K | $577.0K | |
| Other Liabilities Noncurrent | $1.1M | $969.0K | |
| Other Assets Noncurrent | $3.0M | $7.9M | |
| Operating Lease Right Of Use Asset | $20.1M | $23.3M | |
| Operating Lease Liability Noncurrent | $18.5M | $22.0M | |
| Operating Lease Liability Current | $4.8M | $4.6M | |
| Operating Lease Expense | $3.1M | $2.9M | |
| Liabilities Current | $22.6M | $20.7M | |
| Liabilities And Stockholders Equity | $397.1M | $240.5M | |
| Liabilities | $42.2M | $43.6M | |
| Common Stock Value | $49.0K | $2.0K | |
| Common Stock Subject To Repurchase | $10.4K | $10.4K | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | -$7.6M | $167.7M | |
| Assets Current | $349.7M | $201.7M | |
| Assets | $397.1M | $240.5M | |
| Accrued Liabilities And Other Liabilities | $16.0M | $14.1M | |
| Accounts Payable Current | $1.8M | $1.9M | |
| Liabilities Fair Value Adjustment | $0.00 | -$8.8M | |
| Temporary Equity Carrying Amount Attributable To Parent | $0.00 | $508.1M | |
| Preferred Stock Value | $0.00 | $0.00 | |
| Offering Costs Recorded In Accounts Payable And Accrued Expenses | $11.0K | $1.1M | |
| Marketable Securities Unrealized Gain Loss | $110.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Stockholders Equity * | $379.4M | $262.2M | $292.1M | -$284.5M | -$262.4M | -$403.7M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $317.9M | $265.6M | $295.5M | $150.7M | $176.2M | $31.1M |
| Cash And Cash Equivalents At Carrying Value | $316.8M | $264.5M | $294.4M | $149.6M | $175.1M | $30.0M |
| Retained Earnings Accumulated Deficit | -$455.0M | -$424.9M | -$391.2M | |||
| Restricted Cash Noncurrent | $1.1M | $1.1M | $1.1M | |||
| Restricted Cash | $1.1M | $1.1M | $1.1M | $1.1M | $1.1M | $1.1M |
| Property Plant And Equipment Net | $5.5M | $6.0M | $6.3M | |||
| Prepaid Expense And Other Assets Current | $7.4M | $6.6M | $5.3M | |||
| Other Operating Activities Cash Flow Statement | $18.0K | $82.0K | ||||
| Other Liabilities Noncurrent | $1.1M | $1.1M | $1.0M | |||
| Other Assets Noncurrent | $3.2M | $3.6M | $3.2M | |||
| Operating Lease Right Of Use Asset | $20.9M | $21.7M | $22.5M | |||
| Operating Lease Liability Noncurrent | $19.4M | $20.3M | $21.1M | |||
| Operating Lease Liability Current | $4.8M | $4.7M | $4.7M | |||
| Operating Lease Expense | $767.0K | $705.0K | ||||
| Liabilities Current | $22.1M | $19.9M | $18.6M | |||
| Liabilities And Stockholders Equity | $422.1M | $303.5M | $332.8M | |||
| Liabilities | $42.6M | $41.3M | $40.8M | |||
| Common Stock Value | $48.0K | $44.0K | $44.0K | |||
| Common Stock Subject To Repurchase | $10.4K | $10.4K | $10.4K | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | $97.6M | $865.0K | ||||
| Assets Current | $391.3M | $271.2M | $299.7M | |||
| Assets | $422.1M | $303.5M | $332.8M | |||
| Accrued Liabilities And Other Liabilities | $14.4M | $11.5M | $11.5M | |||
| Accounts Payable Current | $2.9M | $3.7M | $2.4M | |||
| Liabilities Fair Value Adjustment | -$2.6M | $216.0K | -$4.8M | |||
| Temporary Equity Carrying Amount Attributable To Parent | ||||||
| Preferred Stock Value | $0.00 | $0.00 | ||||
| Offering Costs Recorded In Accounts Payable And Accrued Expenses | ||||||
| Marketable Securities Unrealized Gain Loss | $69.0K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 |
|---|---|---|
| Share Based Compensation | $16.4M | $9.6M |
| Proceeds From Stock Options Exercised | $5.6M | $733.0K |
| Payments To Acquire Property Plant And Equipment | $794.0K | $1.1M |
| Net Cash Provided By Used In Operating Activities | -$111.9M | $76.0M |
| Net Cash Provided By Used In Investing Activities | -$171.0M | -$1.1M |
| Net Cash Provided By Used In Financing Activities | $275.3M | $92.8M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $2.9M | -$93.0K |
| Increase Decrease In Other Operating Liabilities | $3.5M | $3.8M |
| Increase Decrease In Other Operating Assets | -$537.0K | $2.3M |
| Increase Decrease In Operating Lease Liability | -$3.3M | -$2.9M |
| Increase Decrease In Accounts Payable | -$27.0K | -$204.0K |
| Proceeds From Issuance Initial Public Offering | $127.8M | |
| Proceeds From Convertible Promissory Note | $24.5M | |
| Proceeds From Issuance Of Common Stock Under The Two Thousand Twenty Five Employee Stock Purchase Plan | $1.3M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 |
|---|---|---|
| Share Based Compensation | $3.2M | $2.3M |
| Proceeds From Stock Options Exercised | $126.0K | $365.0K |
| Payments To Acquire Property Plant And Equipment | $299.0K | $279.0K |
| Net Cash Provided By Used In Operating Activities | -$29.5M | -$23.4M |
| Net Cash Provided By Used In Investing Activities | -$299.0K | -$279.0K |
| Net Cash Provided By Used In Financing Activities | $127.4M | $24.6M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $474.0K | -$1.1M |
| Increase Decrease In Other Operating Liabilities | -$1.1M | -$131.0K |
| Increase Decrease In Other Operating Assets | -$338.0K | -$208.0K |
| Increase Decrease In Operating Lease Liability | -$805.0K | -$699.0K |
| Increase Decrease In Accounts Payable | $579.0K | -$243.0K |
| Proceeds From Issuance Initial Public Offering | $127.8M | |
| Proceeds From Convertible Promissory Note | $24.2M | |
| Proceeds From Issuance Of Common Stock Under The Two Thousand Twenty Five Employee Stock Purchase Plan |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 |
|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 43.0M | 2.4M |
| Weighted Average Number Of Diluted Shares Outstanding | 43.0M | 2.7M |
| Earnings Per Share Diluted | $-3.05 | $1.25 |
| Earnings Per Share Basic | $-3.05 | $1.42 |
| Common Stock Shares Authorized | 500.0M | 410.0M |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 |
| Common Stock Shares Outstanding | 49.3M | 2.4M |
| Common Stock Shares Issued | 49.3M | 2.4M |
| Preferred Stock Shares Authorized | 10.0M | |
| Preferred Stock Par Or Stated Value Per Share | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 45.8M | 43.8M | 28.6M | 2.4M | 2.4M | 2.3M |
| Weighted Average Number Of Diluted Shares Outstanding | 45.8M | 43.8M | 28.6M | 2.4M | 4.3M | 2.3M |
| Earnings Per Share Diluted | $-0.66 | $-0.77 | $-1.15 | $-10.25 | $3.22 | $-13.91 |
| Earnings Per Share Basic | $-0.66 | $-0.77 | $-1.15 | $-10.25 | $5.92 | $-13.91 |
| Common Stock Shares Authorized | 500.0M | 500.0M | 500.0M | |||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | |||
| Common Stock Shares Outstanding | 48.1M | 43.9M | 43.8M | |||
| Common Stock Shares Issued | 48.1M | 43.9M | 43.8M | |||
| Preferred Stock Shares Authorized | ||||||
| Preferred Stock Par Or Stated Value Per Share |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 |
|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $16.4M | $9.6M |
| Stock Issued During Period Value Stock Options Exercised | $5.6M | $765.0K |
| Interest And Other Income | $11.8M | $4.7M |
| Depreciation | $2.4M | $3.3M |
| Additional Paid In Capital | $844.4M | $47.2M |
| Capital Expenditures Incurred But Not Yet Paid | $5.0K | $59.0K |
| Adjustments To Additional Paid In Capital Vesting Of Restricted Stock And Early Exercised Stock Options | $23.0K | |
| Vestingof Restricted Stock And Stock Options Subject To Repurchase | $23.0K | |
| Stock Issued During Period Value Conversion Of Convertible Securities | $508.1M | |
| Payment Of Success Fee Derivative | $500.0K | |
| Change In Fair Value Of Convertible Promissory Note | $8.8M | |
| Stock Issued During Period Value Employee Stock Purchase Plan | $1.3M | |
| Participating Securities Distributed And Undistributed Earnings Loss Basic |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $3.9M | $3.2M | $3.2M | $2.3M | $2.1M | $2.3M |
| Stock Issued During Period Value Stock Options Exercised | $2.0M | $126.0K | $245.0K | $79.0K | $365.0K | |
| Interest And Other Income | $2.9M | $2.8M | $2.6M | $1.8M | $1.0M | $281.0K |
| Depreciation | $684.0K | $950.0K | ||||
| Additional Paid In Capital | $834.3M | $687.1M | $683.2M | |||
| Capital Expenditures Incurred But Not Yet Paid | $48.0K | $47.0K | ||||
| Adjustments To Additional Paid In Capital Vesting Of Restricted Stock And Early Exercised Stock Options | $5.0K | $6.0K | $11.0K | |||
| Vestingof Restricted Stock And Stock Options Subject To Repurchase | $11.0K | |||||
| Stock Issued During Period Value Conversion Of Convertible Securities | $508.1M | |||||
| Payment Of Success Fee Derivative | $500.0K | |||||
| Change In Fair Value Of Convertible Promissory Note | $4.8M | |||||
| Stock Issued During Period Value Employee Stock Purchase Plan | $612.0K | |||||
| Participating Securities Distributed And Undistributed Earnings Loss Basic | $124.9M |
Most recent annual filing with the SEC: March 25, 2026
Data sourced from SEC EDGAR public filings as of August 4, 2026.